Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

被引：0
作者：
Aejaz Nasir
Timothy R. Holzer
Mia Chen
Michael Z. Man
Andrew E. Schade
机构：
[1] Eli Lilly and Company,Diagnostic and Experimental Pathology
[2] Eli Lilly and Company,Oncology Statistics
[3] Eli Lilly and Company,undefined
[4] Lilly Corporate Center,undefined
来源：
Cancer Cell International | / 17卷
关键词：
Breast cancer; HER2; Angiogenesis; VEGFR2; Ramucirumab; Antiangiogenic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies
    Nasir, Aejaz
    Holzer, Timothy R.
    Chen, Mia
    Man, Michael Z.
    Schade, Andrew E.
    CANCER CELL INTERNATIONAL, 2017, 17
  • [2] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [3] Rational Design of Anti-Angiogenic Peptides to Inhibit VEGF/VEGFR2 Interactions for Cancer Therapeutics
    Ghasemali, Samaneh
    Farajnia, Safar
    Barzegar, Abolfazl
    Rahmati, Mohammad
    Negahdari, Babak
    Rahbarnia, Leila
    Yousefi-Nodeh, Hamidreza
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (10) : 2026 - 2035
  • [4] RNF114 Interacts with EWSR1 to Regulate VEGFR2 in HER2-positive Breast Cancer
    Zhu, Yingchuan
    Song, Yue
    Lu, Yilu
    Jiang, Wenhao
    Zhang, Jingfei
    Yin, Lan
    Lin, Xinyu
    Tao, Dachang
    Ma, Yongxin
    JOURNAL OF CANCER, 2025, 16 (06): : 1888 - 1904
  • [5] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [6] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [7] Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer
    Fink-Retter, Anneliese
    Gschwantler-Kaulich, Daphne
    Hudelist, Gernot
    Mueller, Ruth
    Kubista, Ernst
    Czerwenka, Klaus
    Singer, Christian F.
    ONCOLOGY REPORTS, 2007, 18 (02) : 299 - 304
  • [8] Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
    Kodack, David P.
    Chung, Euiheon
    Yamashita, Hiroshi
    Incio, Joao
    Duyverman, Annique M. M. J.
    Song, Youngchul
    Farrar, Christian T.
    Huang, Yuhui
    Ager, Eleanor
    Kamoun, Walid
    Goel, Shom
    Snuderl, Matija
    Lussiez, Alisha
    Hiddingh, Lotte
    Mahmood, Sidra
    Tannous, Bakhos A.
    Eichler, April F.
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (45) : E3119 - E3127
  • [9] The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs
    Chuang, I-Chen
    Yang, Chih-Min
    Song, Tuzz-Ying
    Yang, Nae-Cherng
    Hu, Miao-Lin
    LIFE SCIENCES, 2015, 139 : 52 - 61
  • [10] In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes
    Das, Sanjib Kumar
    Deka, Suman Jyoti
    Paul, Dipayan
    Gupta, Debmalya Das
    Das, Tridip Jyoti
    Maravi, Devendra Kumar
    Tag, Hui
    Hui, Pallabi Kalita
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (15) : 6857 - 6867
12345